NephRx Corporation
NephRx is a biotechnology company dedicated to the discovery and development of therapeutic products for the treatment of kidney failure/disease, and diseases of the gastrointestinal tract.
The company has made significant progress over the past three years, demonstrating the efficacy of its lead product – a kidney growth factor peptide – in two animal models for acute renal failure.
NephRx will also focus on its second lead product – AMP-18 – a gastric growth factor. Animal studies have been conducted that demonstrate how AMP-18 or one of its peptides can repair the GI tract of animals with ulcerative colitis, Crohn’s disease, mucositis, or gastric ulcers. AMP-18 will also be tested in animal models with chronic wounds.
NephRx is interested in the possibility of co-development relationships, by drug delivery or indication with other pharmaceutical or biotechnology companies.